Log in
NASDAQ:MTCR

Metacrine Stock Forecast, Price & News

$9.10
+0.36 (+4.12 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$8.40
Now: $9.10
$9.20
50-Day Range N/A
52-Week Range
$8.05
Now: $9.10
$16.19
Volume25,933 shs
Average Volume129,276 shs
Market Capitalization$235.89 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases in the United States. It is developing MET409, a therapy that is in a Phase Ib proof-of-concept clinical trial for the treatment of non-alcoholic steatohepatitis patients; and MET642, a candidate, which is in Phase 1 clinical trial for the treatment of non-alcoholic steatohepatitis patients. The company has a research collaboration with Novo Nordisk A/S to perform research activities related to fibroblast growth factor 1. Metacrine, Inc. was founded in 2014 and is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MTCR
CUSIPN/A
CIKN/A
Phone858-369-7800
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$235.89 million
Next Earnings DateN/A
OptionableNot Optionable
$9.10
+0.36 (+4.12 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MTCR News and Ratings via Email

Sign-up to receive the latest news and ratings for MTCR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Metacrine (NASDAQ:MTCR) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Metacrine?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Metacrine in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Metacrine
.

What price target have analysts set for MTCR?

3 equities research analysts have issued 1-year price objectives for Metacrine's shares. Their forecasts range from $18.00 to $25.00. On average, they expect Metacrine's stock price to reach $20.67 in the next year. This suggests a possible upside of 127.1% from the stock's current price.
View analysts' price targets for Metacrine
.

Who are some of Metacrine's key competitors?

What other stocks do shareholders of Metacrine own?

Who are Metacrine's key executives?

Metacrine's management team includes the following people:
  • Ms. Trisha M. Millican, Chief Financial Officer (Age 47, Pay $381.47k)
  • Dr. Hubert C. Chen, Chief Medical Officer (Age 51, Pay $440.14k)
  • Dr. Preston S. Klassen, Pres, CEO & Director (Age 51)
  • Ms. Patricia Millican, Chief Financial Officer (Age 47)
  • Ms. Catherine C. Lee, Sr. VP & Gen. Counsel (Age 46)
  • Ms. Theresa Lowry, VP of HR

When did Metacrine IPO?

(MTCR) raised $84 million in an IPO on Wednesday, September 16th 2020. The company issued 6,500,000 shares at $12.00-$14.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Metacrine's stock symbol?

Metacrine trades on the NASDAQ under the ticker symbol "MTCR."

When did the company's quiet period expire?

Metacrine's quiet period expired on Monday, October 26th. Metacrine had issued 6,540,000 shares in its IPO on September 16th. The total size of the offering was $85,020,000 based on an initial share price of $13.00. During the company's quiet period, insiders and underwriters involved in the IPO were restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Metacrine?

Shares of MTCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Metacrine's stock price today?

One share of MTCR stock can currently be purchased for approximately $9.10.

How big of a company is Metacrine?

Metacrine has a market capitalization of $235.89 million.

What is Metacrine's official website?

The official website for Metacrine is www.metacrine.com.

How can I contact Metacrine?

Metacrine's mailing address is 3985 SORRENTO VALLEY BLVD. SUITE C, SAN DIEGO CA, 92121. The company can be reached via phone at 858-369-7800 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.